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Background: MicroRNAs (miRNAs) are a class of small RNAs that have been linked to a number of diseases
including cancer. The potential application of miRNAs in the diagnostics and therapeutics of ovarian and other
cancers is an area of intense interest. A current challenge is the inability to accurately predict the functional
consequences of exogenous modulations in the levels of potentially therapeutic miRNAs.
Methods: In an initial effort to systematically address this issue, we conducted miRNA transfection experiments
using two miRNAs (miR-7, miR-128). We monitored the consequent changes in global patterns of gene expression
by microarray and quantitative (real-time) polymerase chain reaction. Network analysis of the expression data
was used to predict the consequence of each transfection on cellular function and these predictions were
experimentally tested.
Results: While ~20% of the changes in expression patterns of hundreds to thousands of genes could be attributed
to direct miRNA-mRNA interactions, the majority of the changes are indirect, involving the downstream
consequences of miRNA-mediated changes in regulatory gene expression. The changes in gene expression induced
by individual miRNAs are functionally coordinated but distinct between the two miRNAs. MiR-7 transfection into
ovarian cancer cells induces changes in cell adhesion and other developmental networks previously associated
with epithelial-mesenchymal transitions (EMT) and other processes linked with metastasis. In contrast, miR-128
transfection induces changes in cell cycle control and other processes commonly linked with cellular replication.
Conclusions: The functionally coordinated patterns of gene expression displayed by different families of miRNAs
have the potential to provide clinicians with a strategy to treat cancers from a systems rather than a single
gene perspective.Background
MicroRNAs (miRNAs) are a class of small (18–24
nucleotides) regulatory RNAs that are crucial in many
cellular processes including development, angiogenesis,
cell cycle and cellular migration [1]. These small RNAs
are encoded in the genomes of both unicellular [2] and mul-
ticellular organisms and typically repress gene expression at
the post-transcriptional level [3]. In humans, miRNAs have* Correspondence: john.mcdonald@biology.gatech.edu
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reproduction in any medium, provided the orbeen shown to repress translation (primarily through
degradation of target mRNAs) by interacting with
3’untranslated regions (UTR) in a sequence specific
manner [4,5]. In rare instances, miRNAs have also
been reported to increase translation [6] and/or tran-
scription [7] of target genes.
There is a large and growing body of evidence that
many diseases, including cancer, are associated with
changes in cellular miRNA levels [8]. In cancer, levels of
specific miRNAs have been reported to be significantly
down- or up-regulated in various cancer types indicating
that these regulatory RNAs may be operationally defined
as either tumor suppressor genes or oncogenes depending
upon the cellular context [9]. Based on these findings, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapeutic agents is being actively pursued [10].
A continuing challenge to the effective use of miRNAs
in cancer therapy is our limited ability to accurately pre-
dict the molecular consequences of exogenous perturba-
tions in cellular levels of miRNAs [11]. The difficulty in
anticipating the full molecular consequences of miRNA
therapy may be due, in part, to the limitations of in silico
target prediction algorithms [12] and to the fact that
miRNAs can directly and/or indirectly modulate expres-
sion levels of multiple genes in addition to the intended
target(s) [13].
In an effort to better understand the range of molecu-
lar changes potentially associated with miRNA therapy
for ovarian cancer, we conducted a series of controlled
experiments in which two miRNAs previously impli-
cated in ovarian cancer onset/progression [14] were
individually transfected into a well-defined ovarian can-
cer (HEY) cell line [15], and the consequence on global
patterns of gene expression monitored by microarray
(Affymetrix HG-U133 Plus 2.0) and quantitative (real-
time) polymerase chain reaction (qPCR). Functional pre-
dictions derived from the gene expression analyses
were experimentally validated. Our results imply that
miRNAs may be clinically useful in a systems approach
to cancer therapy.
Results
Ectopic expression of miR-7 or miR-128 significantly
down-regulates EGFR in HEY cells
To assess the biological effectiveness of our transfec-
tions, we monitored changes in levels of EGFR, a pre-
viously validated target of miR-7 and miR-128 [16,17].
These previous findings are consistent with the fact that
the 3’UTR of EGFR contains up to four predicted bind-
ing sites for miR-7 and two predicted binding sites for
miR-128 (Figure 1). Since we previously demonstrated
that EGFR is highly expressed in HEY cells [15], we
expected levels of EGFR mRNA and protein to be signif-
icantly reduced after a successful miR-7 or miR-128
transfection (Additional file 1: Figure S1). Consistent
with this expectation, our results demonstrate that over-
expression of either miR-7 or miR-128 in HEY cells
results in significant down-regulation of EGFR expres-
sion (Figure 2).
miR-7 or miR-128 transfection induces changes in
expression of hundreds to thousands of genes
To study the effect of over-expression of miR-7 or miR-
128 on global patterns of gene expression, we isolated
total RNA from cells 48 hours after transfection and
conducted microarray analysis (HG-U133 Plus 2.0). The
results indicate that transfection of miR-7 induced sig-
nificant changes in the expression of 754 genes (foldchange ≥1.4, FDR ≤5%; Additional file 1: Table S1)
and that miR-128 transfection induced significant
changes in the expression of 2338 genes (Additional
file 1: Table S2), both relative to controls. The number
of genes differentially expressed in both experiments
was 286 (overlap of the two experiments). For miR-7,
the majority of the differentially expressed genes (DEGs)
were down-regulated (599, ~80%), while for cells trans-
fected with miR-128, most (1624, ~70%) of the DEGs
were up-regulated.
Less than 1% of the miR-7 or miR-128 induced changes in
gene expression are the consequence of down-regulation
of EGFR
To eliminate the possibility that miRNA induced
changes in levels of RNA might simply be explained by
the down-regulation of EGFR, we monitored the effect
of EGFR siRNA transfection on global changes in levels
of RNA and contrasted the results with expression pat-
terns observed after miR-7 or miR-128 expression.
After verifying knock-down of EGFR by siRNA trans-
fection (Additional file 1: Figure S2), we monitored
global patterns of gene expression by microarray.
Employing identical criteria to that used for the detec-
tion of differentially expressed genes after the miRNA
transfections (fold change ≥1.4, FDR ≤5%), we found
that only eight genes (in addition to EGFR) displayed a
significant change in levels of RNA (Additional file 1:
Table S3). (Note that the majority of regulatory effects
associated with EGFR knockdown are expected to oper-
ate on the post-transcriptional level and will not be
detected by microarray analyses). Only two of these
genes (including EGFR) are altered in all three transfec-
tions. Three of the genes differentially expressed after
siRNA transfection are also differentially expressed after
miR-7 transfection, only five of the nine are also differ-
entially expressed after miR-128 transfection, and only
three were differentially expressed only in the siRNA
transfection. These findings indicate that the vast major-
ity of changes in levels of mRNA observed after miR-7
or miR-128 transfection are not merely the consequence
of knock-down in EGFR expression.
Less than 20% of the genes differentially expressed after
miR-7 or miR-128 transfection are predicted targets of
these miRNAs
A single miRNA can potentially target hundreds of
genes [18,19]. To explore the possibility that the global
changes in expression patterns observed after miR-7 or
miR-128 transfection were the result of direct targeting,
we first computed the percentage of the down-regulated
genes potentially regulated by miR-7 or miR-128 as
predicted by three major target prediction algorithms
(miRanda, TargetScan, and PicTar). The results indicate
Figure 1 Predicted miR-7 and miR-128 target sites (miRanda) on EGFR (epidermal growth factor receptor gene) 3’UTR (untranslated
region). (A) Nucleotide sequences of miR-128 and miR-7 “seed” regions and complementary “target” sequences on the EGFR UTR. Vertical lines
( | ) denote Watson-Crick base pairing, while the colon (:) sign denotes wobble between G and U on opposite strands. (B) Schematic illustration
of the relative location of each target site on the EGFR gene.
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ferentially expressed after miR-7 or miR-128 transfection
are direct regulatory targets of these miRNAs (Table 1).
For example, of the 599 genes down-regulated after
miR-7 transfection, only 194 or 32.4% are predicted to
be targets of this miRNA by miRanda. The percentages
are lower using targets predicted by the PicTar (6.5%)
and TargetScan (10.2%) algorithms.
Although increased levels of miRNAs are generally
expected to down-regulate the expression of target genes,
there have also been reports of the expression of target
genes being increased after miRNA transfection [7]. If
we include all genes that are either down-regulated or
up-regulated after miR-7 or miR-128 expression, the per-
centage of predicted targets remains, on average, < 20%
(range: 4.6 to 28.2%) (Table 1). We conclude that less
than one-fifth of the genes differentially expressed after
miR-7 or miR-128 transfection are likely the result of reg-
ulatory effects directly exerted by these miRNAs.
The effect of miR-128 transfection on patterns of gene
expression may be partially explained by the de-
repression of endogenous miRNA targets
It has been previously proposed that transfection of
exogenous miRNA molecules may interfere with endo-
genous miRNA targeting of mRNAs due to competi-
tion for a limited number of RNA-Induced Silencing
Complexes (RISC) [20]. According to this model, if
endogenous miRNAs are out competed for RISCs by
exogenous miRNAs, the targets of the endogenous
miRNAs may be expected to be up-regulated. In a pre-transfected cell, endogenous miRNAs with higher expres-
sion values are predicted to have a greater likelihood of
being in the RISC and, thus, more likely to be affected by
introduction of exogenous miRNAs [20,21].
As mentioned above, a majority (~70%) of the 2338
genes displaying significant changes in expression after
miR-128 transfection were up-regulated (Additional file
1: Table S2). We have previously shown that our trans-
fection protocol results in a significant increase in levels
of the transfected miRNA (~ 130X) [22]. To deter-
mine if the RISC competition model might help explain
some of the effects of miR-128 transfection, we sought
to determine if the target sequences of miRNAs most
highly expressed in pre-transfected HEY cells were
significantly enriched in genes up-regulated after miR-
128 transfection.
We employed a previously established gene set enrich-
ment analysis algorithm (Genomica; [23]) to identify
miRNA target sites enriched in mRNAs up-regulated
after miR-128 transfection. The results indicate that tar-
get sites of 78 miRNAs are significantly enriched among
the 1624 genes up-regulated after miR-128 expression
(Additional file 1: Table S4).
To test whether these 78 miRNAs were expressed at
higher levels in pre-transfected HEY cells relative to
all expressed miRNAs, we measured levels of human
miRNAs in pre-transfected HEY cells by microarray
(Affymetrix GeneChip miRNA array; Additional file 1:
Table S5). Out of 847 human miRNAs present on the
chip, 281 were found to be expressed in pre-transfected
HEY cells, and out of the 78 miRNAs with target sites
Figure 2 miRNAs miR-7 and miR-128 down-regulate EGFR in HEY cells. (A & B) Histograms showing the average of independent biological
repicates of qPCR determined EGFR RNA levels following transfection of miR-7 or miR-NC (A), and miR-128 or miR-NC (B) in HEY cells using
GAPDH as the endogenous control. Statistical analysis for qPCR was carried out using randomization (REST 2008 software) [42] with at least 1000
iterations [Note that the REST Software determines gene 95% confidence intervals for gene expression ratios using a bootstrapping technique
without normality or symmetrical distribution assumptions. Thus, the error bars will not necessarily be equal in the plus and minus directions]
(*** p <0.001, ** p <0.05); (C & D) Representative western blots of EGFR protein levels after transfection of miR-7 and miR-NC (C) or miR-128 and
miR-NC (D); (E & F) Histograms showing average densitometric analyses of independent biological replicates of immunoblots measuring protein
levels of EGFR following transfection of miR-7 and miR-NC (E) or, miR-128 and miR-NC (F). Statistical analysis of immunoblots was carried out
using a 2-tailed t-test (** p <0.01).
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fection, 45 were expressed in pre-transfected HEY cells.
Figure 3 displays a histogram of log2 signal values for all
expressed miRNAs (281) and for the subset of miRNAs
(45) with target sites significantly enriched in genes/
mRNAs up-regulated after miR-128 transfection. The
results demonstrate that miRNAs with binding sites
significantly enriched in up-regulated genes display a
significantly greater fraction of signal values above log2
(10) relative to all miRNAs (Mann–Whitney p-value
<0.0001) indicating a generally higher level of expression
in pre-transfected HEY cells. While these findings are
consistent with the hypothesis that at least some of the
increased level of gene expression observed after miR-
128 transfection may be the indirect effect of the
displacement of endogenous miRNAs from the RISC,
they do not exclude alternative hypotheses (e.g., seebelow). In addition, the RISC displacement model does
not explain the 714 genes down regulated after miR-128
transfection. Nor does it explain the vast majority of the
genes differentially expressed after miR-7 transfection.
As reported above, only ~20% of differentially
expressed genes were up-regulated after miR-7 transfec-
tion. When we employed the Genomica gene set enrich-
ment analysis algorithm [23] to identify miRNA target
sites enriched in mRNAs up-regulated after miR-7 trans-
fection only 2 miRNAs were found to be significantly
enriched among the up-regulated genes (Additional file
1: Table S6). Thus, the RISC displacement model does
not explain the up-regulation of genes after miR-7 trans-
fection or the fact that the vast majority of genes were
down-regulated after miR-7 transfection. While the rea-
son for this discrepancy is currently unknown, we note
that there are several previous reports of relatively little
Table 1 Fraction of down-regulated, up-regulated and
total differentially expressed genes predicted to be
targets of miRNAs
miR-7 miR-128
M TS PT AVG M TS PT AVG
Down (%) 32.4 10.2 6.5 16.4 36.0 14.7 9.1 19.9
Up (%) 12.3 1.9 0.6 4.9 18.8 3.8 2.6 8.4
All (%) 28.2 8.5 5.3 14.0 24.0 7.1 4.6 11.9
Significantly down-regulated (Down), up-regulated (Up) or total differentially
expressed genes (All) after miR-7 or miR-128 transfections in HEY cells were
searched for targets of the respective miRNAs using miRanda (M), TargetScan
(TS) and PicTar (PT) algorithms. The fraction (%) of targets within each group
and the average (AVG) of all 3 algorithms are reported in this table.
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[4,13,24,25]. Perhaps other indirect effects of miRNA
transfections (e.g., see below) may override or mask the
consequence of the displacement of endogenous miRNAs
from RISC or possible variability in the binding affinity of
different miRNAs for RISC [26] may modulate the rela-
tive effectiveness of miRNA displacement.
miR-7 or miR-128 transfection may trigger cascades of
indirect regulatory changes in gene expression
GeneGo functional and binding interaction network ana-
lysis was used to identify genes with the most significant
number of interactions (“hub genes”) among genes dif-
ferentially expressed after miR-7 or miR-128 transfection.
miRNA induced changes in the expression level of hub
genes are expected to induce subsequent changes in theFigure 3 Endogenous miRNAs that target up-regulated genes are exp
Frequency distribution of log2 signal values for all 281 miRNAs expressed in
miRNAs expressed among those targeting up-regulated genes after miR-12
targeting up-regulated genes have a greater frequency of being expressed
(signal value) ≤10 (Mann–Whitney p-value <0.0001). Only miRNAs with at l
samples and with a ‘hsa’- prefix in probeset names were used for plotting
signal values between log2 4–14 was calculated and plotted using the ‘datexpression of genes regulated by these hub genes. If
these regulated genes include other hub genes, the regu-
latory “ripple effect” can be significant.
Functional network analysis identified 10 hub genes
among those differentially expressed after miR-7 trans-
fection and 61 among genes differentially expressed after
miR-128 transfection (FDR <0.05). Many of these hub
genes are predicted to be direct targets of miR-7 or
miR-128 regulation (Additional file 1: Table S7 and
Additional file 1: Table S8). For example, the gene
encoding the RELA component of the NF-κB regula-
tory protein is a predicted target of miR-7 and was
significantly down-regulated after miR-7 transfection
(Additional file 1: Table S1). Consistent with the
hypothesis that down-stream effects of RELA may be
contributing to indirect changes in expression levels,
we found that a number of the genes differentially
expressed after miR-7 transfection are documented
targets of NF-κB regulation. Among these is the cyto-
kine IL-1 beta [27] that, in turn, is predicted to regu-
late genes that were also differentially expressed after
miR-7 transfection (Figure 4A, Additional file 1: Table S9).
Similar changes in patterns of gene expression were
observed after miR-128 transfection. For example,
Caveolin-1 (CAV1) is a negative regulator of the Ras-
p42/44 MAP kinase cascade [28]. Levels of CAV1 were
significantly reduced after miR-128 transfection and
down-stream targets of CAV1 were among those genes
significantly differentially expressed (Additional file 1:ressed at relatively higher levels in pre-transfected cells.
HEY cells (grey) compared with signal value distribution for 45
8 transfection (black). The bar chart shows that the 45 miRNAs
at log2 signal value >10, while most miRNAs frequently have log2
east one “TRUE” detection (Additional file 1 Table S5) call across all
the distribution of signal values. Frequency of miRNAs having
a analysis’ package in Microsoft Excel.
Figure 4 (See legend on next page.)
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Figure 4 Examples of how miRNA regulation of hub genes indirectly affect the expression of large numbers of downstream genes.
(A) Among genes differentially expressed after miR-7 transfection, RELA/NF-κB (circled in red) acts as a hub gene, and is found to target many of
the differentially expressed genes. One of these, IL1-beta (circled in red) is significantly down-regulated and targets additional differentially
expressed genes, thus, amplifying the effect of NF-κB down-regulation. (B) Caveolin-1 (circled in red) is a significantly down-regulated hub gene
and a predicted target of miR-128. One of CAV1’s many direct downstream target genes is SMAD2 (also circled in red; regulation shown by
arrow/edge pointing from Caveolin-1 to SMAD2), which itself acts as another hub gene. Several downstream targets of SMAD2 are also
differentially expressed following miR-128 transfection. Thus by targeting the hub gene CAV1, miR-128 can regulate the non-target hub gene
SMAD2 and trigger a ripple effect on the expression of down-stream genes. Key: blue filled circle - significantly down-regulated gene as
determined by microarray analysis; red filled circle – significantly up-regulated gene as determined by microarray analysis; green edges:
established activating interaction; red edges: established inhibitory interaction; grey edges: predicted interaction of unknown significance.
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CAV1 regulated genes displaying significant changes in
expression after miR-128 transfection is another hub
gene, the transcription factor SMAD2 [29]. Genes
known to be trans-regulated by SMAD2 were also differ-
entially expressed after miR-128 transfection (Figure 4B,
Additional file 1: Table S10). Collectively, our results are
consistent with the hypothesis that a major fraction of
the changes in expression induced after miR-7 or miR-
128 transfection are likely the indirect or down-stream
consequences of changes in hub gene expression.
miR-7 and miR-128 transfection modulates changes in the
expression of genes involved in distinct developmental
and cell cycle related pathways
Our results indicate that the direct and indirect effects
of miR-7 and miR-128 transfection on global patterns of
gene expression are quite distinct. Only 286 genes were
in common among the 754 genes differentially expressed
after miR-7 transfection and the 2338 genes differentially
expressed after miR-128 transfection. To evaluate the
potential functional significance of the genes uniquely
differentially expressed after either miR-7 or miR-128
transfection, we subjected the gene expression data to
GeneGo pathway enrichment analysis.
The results of our functional pathway analysis indicate
that genes differentially expressed after miR-7 transfec-
tion are significantly over-represented in 91 functional
pathways (Figure 5A, Additional file 1: Table S11). The
20 most significantly over-represented pathways are
listed in Table 2A and include cell adhesion and other
pathways associated with epithelial-mesenchymal transi-
tion (EMT). We found that genes differentially expressed
after miR-128 transfection are over-represented in 231
pathways (Figure 5B, Additional file 1: Table S12). The
20 most significantly over-represented pathways listed in
Table 2B include a variety of pathways associated with
cell cycle control.
Of the 252 pathways (not additive due to overlap) sig-
nificantly over-represented among genes differentially
expressed after miR-7 or miR-128 transfection, only 71
pathways were found to overlap (including the EGFR
pathway). Among the 20 most significantly enrichedpathways only 3 overlapped. Among genes down-
regulated following miR-7 transfection most pathways are
involved in development (cell adhesion, various signaling
pathways, etc.), while among those down-regulated fol-
lowing miR-128 transfection most pathways are involved
in cell cycle regulation (Figure 5C and 5D, Additional file
1: Table S13 and Additional file 1: Table S14) [Note a
similar analysis of up-regulated genes revealed only 1
pathway enriched for miR-7 and 70 pathways enriched
for miR-128 (Additional file 1: Table S15 and Additional
file 1: 1S16)].
Experimental assays of cell adhesion and cell cycle
control in miR-7 and miR-128 transfected cells are
consistent with predictions from the gene
expression analyses
In an effort to experimentally test the validity of the
computationally predicted consequences of miRNA
transfection on cell function, we conducted assays to
monitor the relative changes in cell adhesion and in cell
cycle control in HEY cells transfected with miR-7 and
miR-128, respectively.
The results of the cell adhesion assays are presented in
Figure 6A and demonstrate a significant increase in cell
adhesiveness in miR-7 transfected cells relative to nega-
tive controls. In contrast, no significant difference
in adhesiveness was observed between miR-128 trans-
fected cells relative to negative controls. These findings
are consistent with the computational prediction that
genes differentially expressed after miR-7 transfection
will be most significantly enriched for genes involved
in cell adhesion (p = 1.31×10-7, Table 2A). Also consis-
tent with the results, genes differentially expressed after
miR-128 transfection were not computationally pre-
dicted to be enriched for genes involved in cell adhesion
(Table 2B).
Flow cytometry was used to monitor the proportion of
cells in various stages of the cell cycle. The results pre-
sented in Figure 6B and Additional file 1: Figure S3
demonstrate that significant differences were detected
among miR-7, miR-128 and control miRNA-transfected
cells for each stage of the cell cycle. miR-7-transfected
cells displayed a significant increase in the proportion of
Figure 5 Genes differentially expressed after miR-7 or miR-128 transfection display distinct pathway signatures. The majority of
pathways enriched (FDR <0.05) among (A) differentially expressed genes after miR-7 transfection, (B) differentially expressed genes after miR-128
transfection are related to development. Cell cycle, cytoskeleton remodeling, apoptosis and signal transduction pathways are also enriched and
may signify cancer specific processes. Distribution of groups of pathways enriched among (C) down-regulated genes after miR-7 transfection or
(D) down-regulated genes after miR-128 transfection indicate that pathways involved in development are the largest fraction of enriched
pathways for miR-7 while genes down-regulated by miR-128 are enriched for pathways involved in cell cycle regulation revealing a distinct
pathway signature for each miRNA.
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portion of cells in the S and G2/M stages of the cell
cycle relative to controls. This finding is consistent with
the computational prediction that genes differentially
expressed after miR-7 transfection are enriched for genes
involved in “Cell cycle_Regulation of G1/S transition”
(p = 8.68×10-7, Table 2A). In contrast, cells transfected
with miR-128 displayed a significant decrease in the pro-
portion of cells in the G0/G1 and an increase in the pro-
portion of cells in S phase of cell cycle relative to
controls. A higher proportion of miR-128 transfected
cells in the supra-G2/M phase of the cell cycle may be
indicative of incomplete chromosomal segregation due
to alterations at the mitotic/metaphase checkpoint.
These observations are consistent with the prediction
that genes differentially expressed after miR-128 trans-
fection are enriched for genes involved in “Cell cycle:
The metaphase checkpoint” (p = 1.01×10-11, Table 2B)and “Cell cycle_Spindle assembly and chromosome
separation” (p = 2.75×10-7, Table 2B).
In general, our experimental studies are consistent
with the computational analysis of our microarray data
indicating that miR-7 and miR-128 transfection modu-
lates changes in the expression of genes predominately
involved in distinct regulatory pathways.Discussion
Although the role of miRNAs and other non-coding
RNAs in the regulation of cellular function is only begin-
ning to be understood, the diagnostic and therapeutic
potential of these regulatory RNAs is already widely
recognized and accepted [30]. Indeed, a number of pre-
clinical trials of miRNAs are currently in progress [10].
The initial results of these studies appear to be generally
supportive of the potential utility of miRNAs in the early
Table 2 Twenty most significantly enriched (FDR<0.05)
GeneGo pathways among differentially expressed genes
after miR-7 (A) or miR-128 (B) transfection into HEY cells
A.
Pathways enriched among miR-7 modulated genes p-value
Cell adhesion_Chemokines and adhesion 1.31E-07
Cell cycle_Regulation of G1/S transition (part 1) 8.68E-07
Cell adhesion_Ephrin signaling 3.96E-06
Development_EGFR signaling pathway 1.02E-05
Development_ERBB-family signaling 1.13E-05
Development_WNT signaling pathway. Part 1.










Proteolysis_Putative ubiquitin pathway 3.44E-05
Development_TGF-beta-dependent induction of
EMT via RhoA, PI3K and ILK.
4.05E-05




Transport_RAB5A regulation pathway 5.75E-05
Cytoskeleton remodeling_TGF, WNT and
cytoskeletal remodeling
7.29E-05
Cell cycle_Regulation of G1/S transition (part 2) 7.30E-05




Translation _Regulation of EIF2 activity 1.01E-04
Cell adhesion_ECM remodeling 1.01E-04
B.
Pathways enriched among miR-128 modulated
genes
p-value
Cell cycle_The metaphase checkpoint 1.01E-11
Cytoskeleton remodeling_TGF, WNT and
cytoskeletal remodeling
1.29E-09
Cell cycle_Role of Nek in cell cycle regulation 1.77E-09
Transport_Clathrin-coated vesicle cycle 4.15E-09
Cell cycle_Initiation of mitosis 4.37E-09
Immune response_Histamine H1 receptor signaling
in immune response
1.78E-07
Cell cycle_Role of APC in cell cycle regulation 1.79E-07
Cell cycle_Spindle assembly and chromosome separation 2.75E-07
Table 2 Twenty most significantly enriched (FDR<0.05)
GeneGo pathways among differentially expressed genes
after miR-7 (A) or miR-128 (B) transfection into HEY cells
(Continued)
Cytoskeleton remodeling_Cytoskeleton remodeling 2.98E-07




Cell cycle_Chromosome condensation in prometaphase 8.18E-07




Translation_Non-genomic (rapid) action of Androgen
Receptor
3.55E-06
Development_PIP3 signaling in cardiac myocytes 4.80E-06
Cytoskeleton remodeling_Role of Activin A in cytoskeleton
remodeling
5.34E-06
Apoptosis and survival_Apoptotic Activin A signaling 5.76E-06
Apoptosis and survival_BAD phosphorylation 6.54E-06
Immune response_Fc epsilon RI pathway 7.40E-06
The pathways that are enriched among differentially expressed genes after
both miR-7 and miR-128 transfection are highlighted in bold.
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remain with respect to their potential therapeutic value.
One of the challenges to the therapeutic use of miR-
NAs is technical in nature and deals with the problemsof packaging and delivering miRNAs to cancer cells.
Significant progress has been made in this area in
recent years and all indications are that these technical
challenges are not insurmountable [33,34]. The second
challenge is more scientific in nature and centers around
our current inability to precisely predict the molecular
consequences of modulating miRNA levels on cell func-
tion. While the exogenous administration of miRNAs
(or “antagomirs”) have been shown to be capable of
effectively regulating targeted oncogenes and tumor
suppressor genes in specific cellular contexts [30], the
indirect effects of perturbing miRNA levels remains
difficult to predict. Since this molecular unpredictability
could translate into clinically unanticipated side-effects,
it may significantly mitigate the intended therapeutic
benefits [11]. It is generally agreed that increased thera-
peutic predictability of miRNAs and other regulatory
RNAs will require a better understanding of the pro-
cesses underlying the molecular function of these mole-
cules in vivo [11].
In an initial effort to systematically dissect the molecu-
lar consequences of exogenously modulating levels of
miRNA in ovarian cancer cells, we transfected two
distinct human miRNAs, miR-7 and miR-128, into a
well-characterized ovarian cancer cell line and moni-
tored the consequent changes on endogenous levels of
gene expression. These specific miRNAs were chosen
because modulations in their levels of expression have
both been previously correlated with ovarian cancer
onset/progression [14].
Figure 6 Experimental validation that miR-7 transfection induces changes in cell adhesion while miR-128 transfection induces changes
in cell cycle control. (A) Percent adhesion for miR-7, miR-128 and negative control (CT) transfected Hey cells to basement membrane extract
(BME). Cells were labeled with 2 μM Calcein AM for 1 hour and 20,000 labeled cells were seeded in BME coated 96-well plate. Each assay was
carried out in triplicate for an adhesion period of 1 hour and 30 minutes. The results demonstrate a significant increase in cell adhesiveness in
miR-7 transfected cells relative to negative controls. No significant difference in adhesiveness was observed between miR-128 transfected cells
relative to negative controls. Each column represents the mean of three individual experiments. Error Bars = standard deviation. (B) Distribution of
miR-7, miR-128 and negative control (CT) transfected Hey cells in specific phases of the cell cycle. MiR-7-transfected cells display a significant
increase in the proportion of cells in G0/G1 and a significant decrease in the proportion of cells in the S and G2/M stages of the cell cycle relative
to controls. Cells transfected with miR-128 display a significant decrease in the proportion of cells in the G0/G1 and an increase in the proportion
of cells in S phase of cell cycle relative to controls. (P-values were determined by ANOVA for each phase of cell cycle for 3 separate transfections.
Error bars = standard deviation).
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resulted in significant changes in expression of hundreds
to thousands of genes. Consistent with the fact that
miR-7 is predicted to target fewer genes than miR-128
(using miRanda, TargetScan or PicTar), we found that
the number of genes differentially expressed after miR-7
transfection was substantially less (approximately one-
third) than that after miR-128 transfection. To determine
if the large number of genes differentially expressed after
the miRNA transfections were likely due to the direct
regulatory action of the miRNAs, we computed the pro-
portions of differentially expressed genes that are direct
targets of miR-7 or miR-128 regulation as predicted
by three different target prediction algorithms. On aver-
age, the proportion of differentially expressed genes pre-
dicted to be directly regulated by either miRNA was less
than one-fifth indicating that most of the changes in
gene expression induced by the miRNA transfections
are indirect.One recently described model to account for indirect
effects of miRNA transfection postulates that transfected
miRNAs may out-compete endogenous miRNAs for
available RISCs [20] and consequently lead to up-
regulation of targets of these endogenous miRNAs. This
model may be relevant with respect to our miR-128
transfection experiment where the majority (70%) of
differentially expressed genes displayed a significant
increase in gene expression.
Consistent with the predictions of the RISC-competition
model, we found that ~60% of the mRNAs enriched for
binding sites of those miRNAs most highly expressed in
pre-transfected HEY cells were significantly over-
represented among mRNAs up-regulated after miR-
128 transfection. While these results do not exclude
alternative explanations, they are consistent with the
hypothesis that at least some of the genes displaying
increased expression after miR-128 transfection may be
explained by the RISC-competition model. The model
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miR-128 transfection or the fact that the vast majority of
genes differentially expressed after miR-7 transfection
were down-regulated. It is also not immediately apparent
why the changes in global patterns of gene expression
induced by the displacement of endogenous miRNAs
should be functionally coordinated.
Perhaps the most commonly observed mechanism
underlying coordinated changes in global patterns of
gene expression involves the modulation of centralized
or “hub” regulatory genes [35]. Hub genes have the
potential to exert control on suites of downstream
genes thereby inducing cascades of regulatory changes
in patterns of gene expression [36]. Network analyses
revealed that a substantial number of genes differentially
expressed after miR-7 or miR-128 transfection are regu-
latory hubs capable of controlling many of the down-
stream genes that were differentially expressed after
miR-7 and miR-128 transfection. These findings indicate
that miRNAs can both directly and indirectly induce
changes in cellular regulatory networks.
In general, our experiments demonstrate that exo-
genous expression of miRNAs in ovarian cancer cells
induces regulatory changes far in excess of those on the
predicted targets. From the clinical perspective, this begs
the question as to whether miRNAs are appropriate
agents for ovarian cancer therapy. Clearly, if the clinical
intent is to precisely silence a specific gene and if the
collateral indirect effects induced by miRNAs are coun-
ter-therapeutic, the answer would be “no”. However, it is
important to keep in mind that miRNAs have been evol-
ving as essential components of the eukaryotic regula-
tory system for millions of years. Thus, the network of
regulatory effects exerted by miRNAs is unlikely to be
random and indeed may eventually provide clinicians
with a strategy to treat ovarian cancer cells from a
systems rather than a single gene perspective.
Our pathway enrichment analysis of the pathways
most significantly affected by miR-7 and miR-128 trans-
fection predicts a significant difference in the functional
consequence of exogenous perturbations in levels of
these two miRNAs. The pathways most significantly
affected by miR-7 transfection are predicted to be
involved with G1/S-phase cell cycle control as well as
cell adhesion and other developmental networks pre-
viously associated with epithelial-mesenchymal transi-
tions (EMT) and other processes linked with metastasis
[37]. In contrast, the pathways most significantly affected
by miR-128 transfection are more focused on mitotic-
phase cell cycle control and other processes commonly
linked with cellular replication [38]. Experimental ana-
lyses of cell adhesion and cell cycle control of cells
transfected by miR-7 and miR-128 respectively were
found to be remarkably consistent with thesecomputational predictions. Although both sets of func-
tions are generally characteristic of ovarian cancer cells,
particular pathways may be relatively more important in
particular tumors.
The therapeutic impact of individual miRNA treat-
ments will ultimately be evaluated at the clinical level.
However, the more we can learn about the processes
underlying functional specialization of different families
of miRNAs in experimentally controlled conditions, the
better positioned we will be to interpret the significance
of changes of these regulatory RNAs in individual
tumors and to rationally select specific miRNAs for
possible use in targeted cancer therapy.
Conclusions
In summary, we have determined that the transfection
of miRNAs into ovarian cancer cells results in changes
in global patterns of gene expression. We have addition-
ally shown that these changes in the expression are
not random but can be explained, in large measure, by
molecular models derived from our current understand-
ing of miRNA function. Clearly, additional studies will
be required to further evaluate the validity of these and
other explanatory models in various classes of ovarian
and other types of cancer cells and other families of
miRNAs. Nevertheless, the results of our present studies
indicate that while the molecular regulatory mechanisms
underlying miRNA functions in vivo are extremely com-
plex, they are not intractable. Validated models that can
be used today to retrospectively explain the impact
of exogenously expressed miRNAs, may be used in the
future to prospectively design optimal system-wide stra-
tegies for the effective treatment of ovarian and other
types of cancer.
Methods
Cell culture and siRNA/miRNA transfection
HEY cells were provided (July, 2005) by Gordon B. Mills
(University of Texas, M. D. Anderson Cancer Center),
freshly recovered from liquid nitrogen (<6 months) and
were cultured according to methods described in [15].
Briefly, the cells (1.5 × 105/well) were seeded on six-well
plates in RPMI 1640 (Mediatech, Manassas, VA) supple-
mented with 10% v/v heat-inactivated fetal calf serum
(Invitrogen, Carlsbad, CA), 2 mM L-glutamine (Media-
tech), 10 mM HEPES buffer (Mediatech), penicillin
(100 U/mL), and streptomycin (100 μg/mL) and allowed
to adhere overnight at 37°C in a 5% CO2 atmosphere.
The following day after washing with PBS and replacing
the growth medium with reduced-serum Opti-MEM
(Invitrogen), cells were transfected with hsa-miR-7 miRI-
DIAN mimic (cat # C-300546), hsa-miR-128 miRIDIAN
mimic (cat # C-300597), miRIDIAN miRNA mimic
negative control #1 (C. elegans miRNA cel-miR-67, with
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ON-TARGET plus siRNA EGFR (cat # L-003114), ON-
TARGET plus siRNA RELA (cat # L-003533) or ON-
TARGET plus non-targeting siRNA negative control
(siNC) (cat # D-001810) (Thermo Fisher Scientific,
Lafayette, CO) using Lipofectamine 2000 (Invitrogen)
according to the manufacturer's instructions at a final
concentration of 25nM (or left untransfected for naïve
cells). All transfections were carried out in duplicates or
triplicates. The cells were incubated with the transfection
medium for 4 hours, washed and allowed to grow in
growth medium (RPMI 1640) for 44 hours before RNA/
protein isolation. Transfection efficiency was estimated
from the relative knock-down of EGFR for miR-7 and the
EGFR siRNA, and from the knock-down of BMI1 for
miR-128 based on the manufacturer’s recommendations
for siRNA/miRNA (Thermo Fisher Scientific).
RNA isolation and whole genome microarray
Total RNA was isolated using the RNeasy Mini RNA
isolation kit (QIAGEN, Valencia, CA). The integrity of
the RNA was verified using an Agilent 2100 Bioanalyzer
(1.8-2.0; Agilent Technologies, Palo Alto, CA). mRNAs
were converted to double stranded (ds)-cDNA and
amplified using Applause 3’-Amp System (NuGen, San
Carlos, CA). This cDNA was fragmented and biotin
labeled using the Encode Biotin Module (NuGen), hybri-
dized to Affymetrix HG-U133 Plus 2.0 oligonucleotide
arrays and analyzed with a GeneChip Scanner 3000
(Affymetrix, Santa Clara, CA).
RNA isolation and miRNA microarray
Total RNA was isolated from two independent samples of
pre-transfected (naïve) HEY cells using the mirVana
miRNA isolation kit according to the manufacturer's
instructions (Applied Biosystems, Foster City, CA). The
quantity and size of small RNAs was verified using an
Agilent 2100 Bioanalyzer (Agilent Technologies). Small
RNAs were labeled with Genisphere FlashTag HSR Biotin
RNA labeling kit (Genisphere, Hatfield, PA) followed by
hybridization with GeneChip miRNA Array chips (Affyme-
trix) according to the manufacturer's instructions. The
chips were washed and then scanned with a GeneChip
Scanner 3000 (Affymetrix). Microarray analyses were per-
formed on 3 independent replicates of negative control
transfected cell samples (miR-NC), 3 independent repli-
cates of miR-7 transfected cell samples and 2 independent
replicates of miR-128 transfected cell samples. Raw data in
the form of CEL files were produced by the Affymetrix
GeneChip Operating System (GCOS) software.
Quantitative (real-time) PCR (qPCR)
Total RNA (1–5 μg) extracted from cells was converted
to cDNA using the Superscript III First Strand SynthesisSystem (Invitrogen). cDNA was then purified using the
Qiagen PCR purification kit following the manufacturer’s
instructions. qPCR experiments were carried out for
the EGFR, BMI1 and GAPDH genes using iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA). The sequence
specific primers used for qPCR are as described in [39]
for EGFR and in [40] for GAPDH. The sequences of the
BMI1 primers were as follows, BMI1-forward: ACTT
CATTGATGCCACAACC, BMI1-reverse: CAGAAG
GATGAGCTGCATAA, and were obtained from the
qPCR primer database RTPrimerDB [41]. All reactions
were optimized with non-template controls, and -RT
(no reverse transcriptase) controls prior to experiment.
All qPCR reactions were carried out using at least 3
technical replicates and 3 biological replicates on the
CFX96 Real Time PCR detection system (Bio-Rad).
Expression values were normalized to the endogenous
control GAPDH. Relative fold change of target RNA
level between transfection groups was determined by the
ΔΔCt method. Statistical significance was determined
using the pair-wise fixed reallocation randomization
test in the Relative Expression Software Tool (REST
2008; [42]).
Cell cycle assays
Hey cells were transfected with miR-7, miR-128 or nega-
tive control miRNA in 3 independent transfection
experiments, and the distribution of the transfected cells
in various phases of the cell cycle was determined by
flow cytometry based on cellular DNA content as pre-
viously described [43]. Equal numbers of transfected
cells were used for DNA staining and FACS analysis (2
x106 cells for each independent experiment). DNA con-
tent histograms were deconvoluted using the Watson
Pragmatic model implemented in FlowJo 7.6 software
(Tree Star Inc., Ashland, OR). Each assay was performed
3 times with independently transfected cells. Statistical
significance of differences among proportions of cells
in specific phases of the cell cycle was tested by
ANOVA followed by Tukey’s Multiple Comparison post-
test (p < 0.05).
Cell adhesion assay
Cell adhesion assays were performed using the Cultre-
Coat BME 96 Well Cell Adhesion Assay Kit (Trevigen,
Gaithersburg, MD) according to the manufacturer's
instructions. Briefly, basement membrane extract (BME)
coated 96-well plates were rehydrated for two hours.
Hey cells transfected with miR-7 or with negative con-
trol miRNA were labeled with 2 μM Calcein AM for
1 hour and then harvested and washed once with PBS.
Cells were suspended in adhesion buffer to a density of
200,000 cells/ml. 100 μl of suspended cells were added
to triplicate wells and incubated at 37°C for 1 hour and
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520 emission (Total RFU). Cells were washed twice with
wash buffer and fluorescence read again (RFU after
wash). Percent adhesion was computed as (RFU after
wash - background) / (Total RFU - background) × 100.
Immunoblotting
Immunoblotting for EGFR and β-Actin was performed as
described previously [44] with the following modifica-
tions. The blots were incubated for 2 hours with goat
anti-rabbit IgG (1:2000) linked to fluorescein (FITC), or
for 1 hour with donkey antimouse IgG (1:5000) linked
to phycoerythrin (PE) secondary antibodies at room tem-
perature (Southern Biotech, Birmingham, AL; primary
anti-EGFR antibodies are described in [44]). Bands were
visualized using a Typhoon 9400 Imager (GE Healthcare,
Piscataway, NJ) followed by densitometric analysis using
the ImageQuant TL Software (GE Healthcare).
Microarray data analysis
miRNA microarray data were analyzed using miRNA
QC Tool software (Version 1.0.33.0; Affymetrix). Probe-
sets with “FALSE” call in all samples were removed prior
to statistical analysis.
mRNA microarray data were analyzed using the
Expression Console software (Affymetrix) and Biocon-
ductor tools [45] written in the R statistical program-
ming language (www.r-project.org). Normalization was
performed using MAS 5.0, PLIER (Expression Console)
and GCRMA (R). The log2 transformed expression
values from MAS 5.0 were analyzed for Affymetrix “Pre-
sent/Absent” calls using Spotfire DecisionSite for Micro-
array Analysis (DSMA). Probesets with “Absent” call in
all samples were removed from analysis. Average probe-
set intensities for each group was calculated based on
the log2 transformed values from PLIER and then filtered
with DSMA to include only those probesets with a fold
change≥ 1.4. The false discovery rate (FDR) for each pro-
beset was calculated from the log2-transformed values
after GCRMA normalization using the SAM algorithm
[46]. Differentially expressed probesets were identified
using a threshold 5% FDR correction, a fold change≥ 1.4
and at least “Present/Marginal” call in one sample. These
three different filtering approaches were used based on
previous recommendations [47] and the combination of
all three was used to achieve the most stringent filtering.
All microarray data are MIAME compliant and have
been submitted to GEO under the accession nos.
GSE29126 and GSE27431.
Pathway enrichment analysis, identification of hub genes
and network building
After identification of DEGs, Pathway Maps analyses
were carried out using GeneGo (http://www.GeneGo.com/) gene ontology software. Hub genes were identified
using the GeneGo interactome analyses with the ‘Signifi-
cant interactions within sets’ algorithm. In all cases sig-
nificance was based on FDR ≤ 0.05. Networks were built
using functional and binding interactions unless tran-
scriptional regulation is specified.miRNA target download
The miRNA targets predictions based on miRanda,
TargetScan and PicTar were downloaded from www.
microrna.org (August 2010 release) [48,49], www.
targetscan.org [19] and from www.pictar.org [18] respec-
tively. “Good” mirSVR score refers to miRNA targets
with <−0.1 score, and “non-good” mirSVR score refers
to targets with >−0.1 score obtained from the support
vector regression algorithm mirSVR, available with
miRanda predictions from www.microrna.org.miRNA target enrichment analysis among up-regulated
genes
Gene set enrichment analysis for predicted miRNA tar-
gets among up-regulated genes was carried out using
the web interface of Genomica (http://genomica.weiz-
mann.ac.il/, accessed July 7, 2010) [23] using default set-
tings. Probeset IDs of up-regulated genes were uploaded
onto the Genomica server for analysis and enrichment
was performed against the ‘Human MicroRNA RNA’
gene set with FDR ≤ 0.05. When only a miRNA family is
identified (without specifying the identity of the paralog)
all members of the family were considered (e.g., hsa-
miR-146a and hsa-miR-146b were both considered when
Genomica identified hsa-miR-146).Additional files
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transfection into HEY cells. Figure S2. Confirmation of EGFR
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